Avidity Biosciences 

Yahoo Finance • 17 days ago

Novartis Drops $1.7 Billion on AI Allergy Breakthrough

This article first appeared on GuruFocus. Novartis (NYSE:NVS) is doubling down on AI-driven drug discovery with a deal that could be worth $1.7 billion, signaling rising conviction that data-intensive platforms may reshape how immunology... Full story

Yahoo Finance • 21 days ago

Dow Inc. (DOW): A Bull Case Theory

We came across a bullish thesis on Dow Inc. on Quipus Capital’s Substack. In this article, we will summarize the bulls’ thesis on DOW. Dow Inc.'s share was trading at $23.86 as of December 2nd. DOW’s trailing and forward P/E were 32.65 and... Full story

Yahoo Finance • 22 days ago

Avidity Biosciences, Inc. (RNA): A Bull Case Theory

We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by  AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.'s share was trading at $71.54 as of December 2... Full story

Yahoo Finance • 23 days ago

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

Key Points Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no shares of MBX at the end of t... Full story

Yahoo Finance • 29 days ago

Guru Fundamental Report for RNA

Below is Validea's guru fundamental report for AVIDITY BIOSCIENCES INC (RNA). Of the 22 guru strategies we follow, RNA rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy l... Full story

Yahoo Finance • last month

Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • last month

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its M... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ("SpinCo") Clear path forward aligned... Full story

Yahoo Finance • 2 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)

BALA CYNWYD, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

We recently published 10 Stocks With Easy 20-40% Gains. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the last week's best-performing stocks. Avidity Biosciences climbed by 42.1 percent week-on-week, as investors gobbled up shares afte... Full story

Yahoo Finance • 2 months ago

RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity sharehold... Full story

Yahoo Finance • 2 months ago

Novartis Profit Rises on Cancer Drug Momentum

This article first appeared on GuruFocus. Novartis (NYSE:NVS) had a solid quarter, with strong sales of its cancer drugs giving profits a nice lift. The Swiss pharma giant said core operating profit rose 6% year over year to $5.5 billion... Full story

Yahoo Finance • 2 months ago

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Argus upgraded Warner Bros. Discovery... Full story

Yahoo Finance • 2 months ago

Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger

We recently published 10 Big Names Crushing Wall Street. Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the top-performing stocks on Monday. Dyne Therapeutics soared by 41.18 percent on Monday to close at $24.17 apiece following a comment... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis

We recently published 10 Big Names Crushing Wall Street. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the top-performing stocks on Monday. Shares of Avidity rallied to a new all-time high on Monday, as investors gobbled up shares foll... Full story

Yahoo Finance • 2 months ago

Novartis Q3 profit swells as oncology drugs drive growth

[Novartis] TBE/iStock Editorial via Getty Images Novartis (NYSE:NVS [https://seekingalpha.com/symbol/NVS]) reported a solid profit increase last quarter, driven by strong demand for its new cancer drugs. Core operating profit rose 6% Y/Y... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Increase Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Novartis To Buy Avidity Biosciences In $12 Billion Rare-Disease Deal

This article first appeared on GuruFocus. Novartis (NYSE:NVS) is making another big bet on cutting-edge medicine. The Swiss pharma giant said Sunday it will buy California-based Avidity Biosciences (NASDAQ:RNA) in a $12 billion all-cash d... Full story

Yahoo Finance • 2 months ago

Novartis CEO defends $12 billion deal for Avidity as 'appropriate risk to take'

By Bhanvi Satija LONDON (Reuters) -Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm getting late-stage data for its muscle disorder treatment next year, saying it was "... Full story

Yahoo Finance • 2 months ago

Top Stock Movers Now: Qualcomm, Keurig Dr Pepper, Newmont, Novartis, and More

Matthias Balk / picture alliance / Getty Images Qualcomm shares surged Monday after the chipmaker announced two new AI chips for data centers. Key Takeaways Major U.S. equities indexes climbed to fresh records in intraday trading Monday... Full story